OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum Forum to be held in Chicago, IL, on June 1, 2018

Alexis Peyroles, chief executive officer, will provide a Company update, including recent accomplishments and future plans, at the upcoming 4th Annual Immuno-Oncology: BD&L and Investment Forum…


OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications

The new patent extends the U.S. protection of Tedopi® to several combinations of  neoepitopes…


COO, Alexis Peyroles, recently interviewed by SCRIP’s Lucie Ellis at EBDgroup’s BIOEurope conference

Access to the interview

OSE Immunotherapeutics blocks SIRPA to feed and rewire myeloid cells in cancer – The flipside of CD47

OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology